Sangamo Therapeutics, Inc. (SGMOQ)
0.161
-0.01
(-3.13%)
USD |
OTCM |
Sep 04, 16:00
Sangamo Therapeutics Research and Development Expense (Quarterly) : 26.57M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 26.57M |
| December 31, 2025 | 31.44M |
| September 30, 2025 | 28.69M |
| June 30, 2025 | 27.08M |
| March 31, 2025 | 25.45M |
| December 31, 2024 | 23.54M |
| September 30, 2024 | 32.11M |
| June 30, 2024 | 24.75M |
| March 31, 2024 | 35.28M |
| December 31, 2023 | 51.21M |
| September 30, 2023 | 59.99M |
| June 30, 2023 | 58.95M |
| March 31, 2023 | 63.22M |
| December 31, 2022 | 66.18M |
| September 30, 2022 | 65.12M |
| June 30, 2022 | 60.02M |
| March 31, 2022 | 58.58M |
| December 31, 2021 | 51.80M |
| September 30, 2021 | 62.50M |
| June 30, 2021 | 60.09M |
| March 31, 2021 | 56.43M |
| December 31, 2020 | 52.36M |
| September 30, 2020 | 45.29M |
| June 30, 2020 | 41.52M |
| March 31, 2020 | 41.48M |
| Date | Value |
|---|---|
| December 31, 2019 | 38.33M |
| September 30, 2019 | 36.29M |
| June 30, 2019 | 36.46M |
| March 31, 2019 | 34.85M |
| December 31, 2018 | 33.25M |
| September 30, 2018 | 28.81M |
| June 30, 2018 | 29.26M |
| March 31, 2018 | 23.55M |
| December 31, 2017 | 19.38M |
| September 30, 2017 | 18.42M |
| June 30, 2017 | 14.98M |
| March 31, 2017 | 12.94M |
| December 31, 2016 | 13.89M |
| September 30, 2016 | 17.01M |
| June 30, 2016 | 19.45M |
| March 31, 2016 | 15.27M |
| December 31, 2015 | 19.91M |
| September 30, 2015 | 16.69M |
| June 30, 2015 | 15.62M |
| March 31, 2015 | 14.98M |
| December 31, 2014 | 14.99M |
| September 30, 2014 | 16.29M |
| June 30, 2014 | 13.43M |
| March 31, 2014 | 12.03M |
| December 31, 2013 | 10.78M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 192.06M |
| Oncolytics Biotech, Inc. | 4.262M |
| Sarepta Therapeutics, Inc. | 91.26M |
| Anixa Biosciences, Inc. | 1.258M |
| Vicapsys Life Sciences, Inc. | 0.00 |